A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

Trial Profile

A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Fibrosis; Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Aug 2017 Planned initiation date changed from 29 Nov 2017 to 12 Feb 2018.
    • 23 May 2017 Planned End Date changed from 13 Oct 2018 to 12 Jan 2019.
    • 23 May 2017 Planned primary completion date changed from 21 Jul 2018 to 12 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top